Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Saskatchewan

$17,500.00

Specific Targeting of Monomeric SOD1 as a Potential Immunotherapeutic Strategy for ALS.

FY 2010-11

Summary
Amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of motor neurons leading to spasticity, over responsive reflexes, generalized weakness, muscle atrophy, paralysis, and death, primarily due to respiratory failure, within 1 to 5 years of onset. Approximately 10% of ALS cases are familial, the remainder sporadic in origin, with 20% of familial cases resulting from mutations in the cellular protein Cu/Zn superoxide dismutase (SOD1). The mutations in this protein destabilize the folding structure resulting in misfolding and an increased tendency toward formation of aggregates. A key component of ALS pathology is hypothesized to involve secretion of the misfolded SOD1 into the extracellular environment and migration of the misfolded SOD1 to other cells. The significant involvement of mutant SOD1 secretion and extracellular toxicity in familial ALS pathogenesis greatly increases the potential efficacy of immunotherapy. The sequence of events leading to motor neuron degeneration in ALS has yet to be solidified. This has greatly impeded the development of an effective treatment to significantly reduce symptoms and increase life expectancy following diagnosis. The primary objective of this research project is to develop a therapeutic vaccine for ALS, which is capable of inducing an effective antibody response against the pathogenic misfolded SOD1, in order to delay onset or progression of the disease symptoms. This project encompasses the preliminary research and development stages for a potential treatment of a devastating human disease, with the goal of improving patient health.
Program
Master's Award: Canada Graduate Scholarships
Location
Saskatchewan, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
225007
Name
Marciniuk Kristen
Region
Saskatchewan
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
Specific Targeting of Monomeric SOD1 as a Potential Immunotherapeutic Strategy for ALS.
Programtype2
Studentship Programs
Orgnameinp2
University of Saskatchewan
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Als; Disease Specific Epitopes; Immunotherapy; Protein Misfolding; Recombinant Fusions; Sod1
Abstract
Amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig's disease, is a progressive neurodegenerative disorder characterized by the selective loss of motor neurons leading to spasticity, over responsive reflexes, generalized weakness, muscle atrophy, paralysis, and death, primarily due to respiratory failure, within 1 to 5 years of onset. Approximately 10% of ALS cases are familial, the remainder sporadic in origin, with 20% of familial cases resulting from mutations in the cellular protein Cu/Zn superoxide dismutase (SOD1). The mutations in this protein destabilize the folding structure resulting in misfolding and an increased tendency toward formation of aggregates. A key component of ALS pathology is hypothesized to involve secretion of the misfolded SOD1 into the extracellular environment and migration of the misfolded SOD1 to other cells. The significant involvement of mutant SOD1 secretion and extracellular toxicity in familial ALS pathogenesis greatly increases the potential efficacy of immunotherapy. The sequence of events leading to motor neuron degeneration in ALS has yet to be solidified. This has greatly impeded the development of an effective treatment to significantly reduce symptoms and increase life expectancy following diagnosis. The primary objective of this research project is to develop a therapeutic vaccine for ALS, which is capable of inducing an effective antibody response against the pathogenic misfolded SOD1, in order to delay onset or progression of the disease symptoms. This project encompasses the preliminary research and development stages for a potential treatment of a devastating human disease, with the goal of improving patient health.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marciniuk, Kristen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~